What is HC Wainwright’s Estimate for Metagenomi Q4 Earnings?

Metagenomi, Inc. (NASDAQ:MGX) – Stock analysts at HC Wainwright increased their Q4 2024 earnings estimates for Metagenomi in a research report issued on Thursday, November 21st. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.52) for the quarter, up from their previous forecast of ($0.69). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Metagenomi’s current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Metagenomi’s Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.69) EPS and FY2025 earnings at ($2.48) EPS.

Other research analysts have also recently issued reports about the company. Chardan Capital restated a “buy” rating and set a $15.00 price target on shares of Metagenomi in a research note on Wednesday, November 20th. BMO Capital Markets decreased their target price on Metagenomi from $22.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday, August 15th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Metagenomi presently has a consensus rating of “Moderate Buy” and an average price target of $15.50.

Metagenomi Stock Performance

Shares of MGX stock opened at $2.01 on Monday. The firm’s 50 day moving average price is $2.06 and its 200-day moving average price is $3.67. Metagenomi has a one year low of $1.61 and a one year high of $12.74.

Institutional Trading of Metagenomi

Several hedge funds have recently modified their holdings of MGX. Vanguard Group Inc. purchased a new stake in Metagenomi during the 1st quarter worth about $1,894,000. Green Alpha Advisors LLC purchased a new stake in shares of Metagenomi during the third quarter worth approximately $69,000. Rhumbline Advisers acquired a new stake in Metagenomi in the second quarter valued at approximately $26,000. Novo Holdings A S lifted its stake in Metagenomi by 3.5% in the second quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock worth $7,344,000 after acquiring an additional 60,825 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Metagenomi during the 2nd quarter worth approximately $66,000.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.